Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK7 | Q8TDX7 | 16/20 | 0.51 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | ABL2 | P42684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075506 | 0.88 | NEK7 (0.51) | NEK7EIF2AK3RIPK2ABL1EGFR | |
| SCHEMBL2071744 | 0.87 | RIPK2 (0.51) | NEK7EIF2AK3RIPK2ABL1EGFR | |
| SCHEMBL2076003 | 0.87 | RIPK2 (0.51) | NEK7EIF2AK3RIPK2ABL1EGFR | |
| SCHEMBL12934104 | 0.87 | EIF2AK3 (0.54) | NEK7EIF2AK3RIPK2ABL1EGFR | |
| SCHEMBL2074412 | 0.86 | EGFR (0.54) | NEK7EIF2AK3RIPK2ABL1EGFR | |
| SCHEMBL2074338 | 0.85 | EIF2AK3 (0.53) | NEK7EIF2AK3RIPK2ABL1EGFR | |
| SCHEMBL2073071 | 0.84 | EIF2AK3 (0.56) | NEK7EIF2AK3RIPK2ABL1EGFR | |
| SCHEMBL2074983 | 0.84 | EIF2AK3 (0.54) | NEK7EIF2AK3RIPK2ABL1EGFR | |
| SCHEMBL2075874 | 0.84 | NEK7 (0.54) | NEK7EIF2AK3RIPK2ABL1EGFR | |
| SCHEMBL2071940 | 0.84 | EGFR (0.55) | NEK7EIF2AK3RIPK2ABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1114052-B1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2005-11-16 | — | — | EP | claimed |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-10-02 | — | — | US | claimed |
| EP-1114052-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | claimed |
| WO-2000017202-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | claimed |
| US-7863444-B2 | 4-aminopyrrolopyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863444-B2 | 4-aminopyrrolopyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1114052-B1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2005-11-16 | — | — | EP | disclosed |
| EP-1225173-B1 | NAPHTHYRIDINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2005-09-28 | — | — | EP | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-6740662-B1 | HAVING 2-OXO-1,2-DIHYDRO- FUNCTIONALITY; PHOSPHODIESTERASE INHIBITORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-25 | — | — | US | disclosed |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-10-02 | — | — | US | disclosed |
| EP-1225173-A1 | NAPHTHYRIDINE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2002-07-24 | — | — | EP | disclosed |
| EP-1114052-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017202-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | NEK7 3001/4885EIF2AK3 3756/4885RIPK2 2575/4885 |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | LCK, PPP5C, DUSP1 | NEK7 2079/4885EIF2AK3 1113/4885RIPK2 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.